Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | ERN1 | O75460 | 6/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | MPL | P40238 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | IL6 | P05231 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579693 | 0.74 | CYP2A6 (0.52) | CYP2A6ERN1MEN1LMNATHRB | |
| SCHEMBL30788041 | 0.74 | MPL (0.41) | MAOAMAOBSLC9A1MPLMEN1 | |
| SCHEMBL29942819 | 0.74 | CYP2A6 (0.52) | CYP2A6ERN1PIM1PIM3MEN1 | |
| SCHEMBL4604059 | 0.74 | CYP2A6 (0.52) | CYP2A6ERN1PIM1PIM3MEN1 | |
| SCHEMBL29160952 | 0.74 | MPL (0.41) | MAOAMAOBSLC9A1MPLMEN1 | |
| SCHEMBL17139919 | 0.74 | MEN1 (0.36) | CYP2A6MAOAMAOBSLC9A1MPL | |
| SCHEMBL20954351 | 0.73 | CYP2A6 (0.51) | CYP2A6ERN1PIM1PIM3NFKB1 | |
| SCHEMBL31722391 | 0.72 | CYP2A6 (0.46) | CYP2A6ERN1 | |
| SCHEMBL5351904 | 0.72 | TAS2R14 (0.41) | SLC9A1MEN1LMNAKMT2A | |
| SCHEMBL17207797 | 0.71 | SLC9A1 (0.42) | MAOBSLC9A1MPLMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101090896-B | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACEUTICA NV | 2011-10-26 | — | — | CN | disclosed |
| EP-1794143-B8 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1794143-B1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | SMITH-SWINTOSKY VIRGINIA L | 2007-12-20 | — | — | US | disclosed |
| CN-101090896-A | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-19 | — | — | CN | disclosed |
| WO-2007095613-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095609-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095608-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASE MODIFICATION OF EPILEPTOGENESIS | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095615-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENTOF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191449-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191460-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191450-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| EP-1794143-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | ABDEL-MAGID AHMED F | 2006-12-07 | — | — | US | disclosed |
| WO-2006023861-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACAEUTICA N.V. (BE) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRA5, SULT2A1, SYNGR2 | CYP2A6 135/4885ERN1 4413/4885PIM1 4173/4885 |
| US-20070191449-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression | TPH2, SULT2A1, SDHA | CYP2A6 464/4885ERN1 4831/4885PIM1 3390/4885 |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | NLN, CTSA, SMN1; SMN2 | CYP2A6 2859/4885ERN1 3139/4885PIM1 4427/4885 |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRE, GABRB2, GABRA2 | CYP2A6 223/4885ERN1 4454/4885PIM1 4270/4885 |
| US-20070191460-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis | SULT2A1, GABRB2, GABRB1 | CYP2A6 143/4885ERN1 3974/4885PIM1 4568/4885 |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | LIPC, GPR119, APOB | CYP2A6 484/4885ERN1 4588/4885PIM1 2870/4885 |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | GABBR1, SYNGR2, GABBR2 | CYP2A6 272/4885ERN1 4715/4885PIM1 4343/4885 |
| US-20070191450-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder | GABBR1, GABBR2, GABRB2 | CYP2A6 381/4885ERN1 4834/4885PIM1 3824/4885 |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, SULT2A1, OPRK1 | CYP2A6 326/4885ERN1 4693/4885PIM1 3985/4885 |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SULT2A1, SULT1A1, STS | CYP2A6 146/4885ERN1 4015/4885PIM1 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.